BioMarin Pharmaceutical Inc. to Post FY2025 Earnings of $3.03 Per Share, William Blair Forecasts (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Analysts at William Blair issued their FY2025 EPS estimates for shares of BioMarin Pharmaceutical in a report issued on Wednesday, April 24th. William Blair analyst T. Lugo anticipates that the biotechnology company will post earnings of $3.03 per share for the year. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $1.85 per share.

Several other equities research analysts also recently issued reports on the stock. Royal Bank of Canada restated a “sector perform” rating and set a $100.00 price objective on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $110.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, April 25th. Morgan Stanley cut their target price on shares of BioMarin Pharmaceutical from $115.00 to $112.00 and set an “overweight” rating on the stock in a research report on Friday. Piper Sandler decreased their price target on shares of BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Finally, Wells Fargo & Company upped their target price on BioMarin Pharmaceutical from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $107.50.

BioMarin Pharmaceutical Stock Up 1.5 %

BMRN opened at $82.13 on Monday. The stock has a market cap of $15.50 billion, a PE ratio of 76.76, a price-to-earnings-growth ratio of 1.36 and a beta of 0.31. The stock’s fifty day simple moving average is $87.45 and its 200 day simple moving average is $89.11. BioMarin Pharmaceutical has a 1-year low of $76.02 and a 1-year high of $99.56. The company has a current ratio of 2.51, a quick ratio of 1.57 and a debt-to-equity ratio of 0.12.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. BioMarin Pharmaceutical had a net margin of 8.31% and a return on equity of 5.39%. The business had revenue of $646.21 million during the quarter, compared to analysts’ expectations of $639.53 million. During the same period last year, the business earned $0.11 earnings per share. The firm’s revenue was up 20.2% on a year-over-year basis.

Insiders Place Their Bets

In other news, insider Henry J. Fuchs sold 35,341 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $85.18, for a total value of $3,010,346.38. Following the completion of the sale, the insider now owns 212,117 shares in the company, valued at approximately $18,068,126.06. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Henry J. Fuchs sold 35,341 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the completion of the sale, the insider now owns 212,117 shares in the company, valued at $18,068,126.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Erin Burkhart sold 2,286 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $90.00, for a total value of $205,740.00. Following the completion of the transaction, the chief accounting officer now owns 16,156 shares in the company, valued at approximately $1,454,040. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 103,229 shares of company stock worth $9,062,967. Insiders own 1.84% of the company’s stock.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Large investors have recently made changes to their positions in the stock. Stratos Wealth Partners LTD. boosted its position in shares of BioMarin Pharmaceutical by 2.1% in the fourth quarter. Stratos Wealth Partners LTD. now owns 5,709 shares of the biotechnology company’s stock valued at $550,000 after acquiring an additional 115 shares during the period. CWM LLC boosted its holdings in BioMarin Pharmaceutical by 10.0% during the 3rd quarter. CWM LLC now owns 1,301 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 118 shares during the period. KB Financial Partners LLC increased its stake in shares of BioMarin Pharmaceutical by 51.3% in the third quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company’s stock worth $31,000 after buying an additional 118 shares during the period. First Horizon Advisors Inc. boosted its holdings in shares of BioMarin Pharmaceutical by 33.3% during the fourth quarter. First Horizon Advisors Inc. now owns 576 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 144 shares during the period. Finally, Atria Wealth Solutions Inc. lifted its holdings in BioMarin Pharmaceutical by 1.6% in the 4th quarter. Atria Wealth Solutions Inc. now owns 9,729 shares of the biotechnology company’s stock worth $938,000 after buying an additional 153 shares during the period. 98.71% of the stock is owned by institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.